Importantly, the findings not only reveal a new mechanism regulation of the progression of NAFLD, but also proposed a novel therapeutic approach to combat NAFLD by targeting Adgrf1. Here, ADGRF1 is linked to metabolic dysfunction-associated steatotic liver disease.